CA3251880A1 - DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF GUILLAIN-BARRÉ SYNDROME WITH THE ANTI-C5 ANTIBODY CROVALIMAB - Google Patents

DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF GUILLAIN-BARRÉ SYNDROME WITH THE ANTI-C5 ANTIBODY CROVALIMAB

Info

Publication number
CA3251880A1
CA3251880A1 CA3251880A CA3251880A CA3251880A1 CA 3251880 A1 CA3251880 A1 CA 3251880A1 CA 3251880 A CA3251880 A CA 3251880A CA 3251880 A CA3251880 A CA 3251880A CA 3251880 A1 CA3251880 A1 CA 3251880A1
Authority
CA
Canada
Prior art keywords
antibody
subject
crovalimab
dose
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3251880A
Other languages
English (en)
French (fr)
Inventor
Simon Bertrand Marie Buatois
Keisuke Gotanda
Kenji SHINOMIYA
Alexandre Antoine Bernard Sostelly
Antoine Paul Maxence SOUBRET
Original Assignee
F Hoffmann La Roche AG
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Chugai Pharmaceutical Co Ltd filed Critical F Hoffmann La Roche AG
Publication of CA3251880A1 publication Critical patent/CA3251880A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3251880A 2022-04-04 2023-04-03 DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF GUILLAIN-BARRÉ SYNDROME WITH THE ANTI-C5 ANTIBODY CROVALIMAB Pending CA3251880A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166585.4 2022-04-04
EP22166585 2022-04-04
PCT/EP2023/058608 WO2023194273A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (1)

Publication Number Publication Date
CA3251880A1 true CA3251880A1 (en) 2023-10-12

Family

ID=81327202

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3251880A Pending CA3251880A1 (en) 2022-04-04 2023-04-03 DOSAGE AND ADMINISTRATION REGIMEN FOR THE TREATMENT OR PREVENTION OF GUILLAIN-BARRÉ SYNDROME WITH THE ANTI-C5 ANTIBODY CROVALIMAB

Country Status (11)

Country Link
US (1) US20250236662A1 (https=)
EP (1) EP4504774A1 (https=)
JP (1) JP2025511382A (https=)
KR (1) KR20240168984A (https=)
CN (1) CN118974082A (https=)
AU (1) AU2023249891A1 (https=)
CA (1) CA3251880A1 (https=)
IL (1) IL314751A (https=)
MX (1) MX2024012073A (https=)
TW (1) TW202404632A (https=)
WO (1) WO2023194273A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388235B2 (en) * 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CR20220040A (es) * 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab

Also Published As

Publication number Publication date
MX2024012073A (es) 2024-11-08
CN118974082A (zh) 2024-11-15
WO2023194273A1 (en) 2023-10-12
US20250236662A1 (en) 2025-07-24
EP4504774A1 (en) 2025-02-12
AU2023249891A1 (en) 2024-08-08
AU2023249891A9 (en) 2024-08-15
JP2025511382A (ja) 2025-04-15
TW202404632A (zh) 2024-02-01
KR20240168984A (ko) 2024-12-02
IL314751A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
CN114173816A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
WO2019186369A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
WO2021091706A1 (en) Treatment for sjögren's syndrome
US20250236662A1 (en) Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab
US20250236661A1 (en) Dosage and administration regimen for the treatment or prevention of guillan-barre syndrome by the use of the anti-05 antibody crovalimab
US20230203149A1 (en) Treatment of atopic dermatitis
CN104395343A (zh) 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案
KR102628314B1 (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
WO2022234440A1 (en) Treatment for lupus nephritis using anti-baffr antibodies
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
WO2025096435A1 (en) Treatment of complement-associated renal diseases
CN119546641A (zh) 用baff或baff受体抑制性抗体的aiha的治疗
Broyles Population Pharmacokinetics of Rituximab in Membranous Nephropathy Patients
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法
TW202345897A (zh) 每月投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
TW202345896A (zh) 每兩週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
IL298882A (en) Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
JP2023504679A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240813

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250116

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250116

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250116

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250117

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250310

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250310

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250320

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250904

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260323

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260323